Cargando…
The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
BACKGROUND: Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467240/ https://www.ncbi.nlm.nih.gov/pubmed/34563187 http://dx.doi.org/10.1186/s12917-021-03014-5 |
_version_ | 1784573346680143872 |
---|---|
author | Klein, Stephanie Nolte, Ingo Rumstedt, Katja Sehn, Maximiliane Raue, Jonathan Friedemann Weiner, Franziska Treese, Julia Sophie Beyerbach, Martin Bach, Jan-Peter |
author_facet | Klein, Stephanie Nolte, Ingo Rumstedt, Katja Sehn, Maximiliane Raue, Jonathan Friedemann Weiner, Franziska Treese, Julia Sophie Beyerbach, Martin Bach, Jan-Peter |
author_sort | Klein, Stephanie |
collection | PubMed |
description | BACKGROUND: Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated. Some positive effects concerning life quality and a decrease in cardiac biomarkers could be verified. This study aimed to further investigate these results using a placebo-controlled double-blinded crossover design. Out of a total of 15 dogs, eight were allocated to sequence-group AB, in which dogs received pimobendan (A) during the first treatment period and placebo (B) during the second period. Accordingly, sequence-group BA was treated first with placebo followed by pimobendan. Each treatment period lasted six months and included a baseline investigation and follow-ups after 90 and 180 days. The investigations included a questionnaire completed by the owners, echocardiographic examination, and measurements of NT-proBNP, cTnI and lactate before and after a standardised submaximal exercise test. RESULTS: NT-proBNP values decreased significantly during the treatment period with pimobendan, and the post-exercise increase was attenuated at day 180. No significant treatment effects could be verified for cTnI and lactate, neither pre- nor post-exercise. Left ventricular size decreased under treatment, whereas no significant changes in left atrial size were detected. The owners described their dogs under treatment with pimobendan as being more active at day 90 (11/15) and day 180 (12/15). Those animals treated with placebo were described as being more active at day 90 (2/15) and day 180 (5/15). CONCLUSIONS: Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-021-03014-5. |
format | Online Article Text |
id | pubmed-8467240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84672402021-09-28 The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study Klein, Stephanie Nolte, Ingo Rumstedt, Katja Sehn, Maximiliane Raue, Jonathan Friedemann Weiner, Franziska Treese, Julia Sophie Beyerbach, Martin Bach, Jan-Peter BMC Vet Res Research BACKGROUND: Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated. Some positive effects concerning life quality and a decrease in cardiac biomarkers could be verified. This study aimed to further investigate these results using a placebo-controlled double-blinded crossover design. Out of a total of 15 dogs, eight were allocated to sequence-group AB, in which dogs received pimobendan (A) during the first treatment period and placebo (B) during the second period. Accordingly, sequence-group BA was treated first with placebo followed by pimobendan. Each treatment period lasted six months and included a baseline investigation and follow-ups after 90 and 180 days. The investigations included a questionnaire completed by the owners, echocardiographic examination, and measurements of NT-proBNP, cTnI and lactate before and after a standardised submaximal exercise test. RESULTS: NT-proBNP values decreased significantly during the treatment period with pimobendan, and the post-exercise increase was attenuated at day 180. No significant treatment effects could be verified for cTnI and lactate, neither pre- nor post-exercise. Left ventricular size decreased under treatment, whereas no significant changes in left atrial size were detected. The owners described their dogs under treatment with pimobendan as being more active at day 90 (11/15) and day 180 (12/15). Those animals treated with placebo were described as being more active at day 90 (2/15) and day 180 (5/15). CONCLUSIONS: Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-021-03014-5. BioMed Central 2021-09-25 /pmc/articles/PMC8467240/ /pubmed/34563187 http://dx.doi.org/10.1186/s12917-021-03014-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Klein, Stephanie Nolte, Ingo Rumstedt, Katja Sehn, Maximiliane Raue, Jonathan Friedemann Weiner, Franziska Treese, Julia Sophie Beyerbach, Martin Bach, Jan-Peter The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
title | The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
title_full | The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
title_fullStr | The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
title_full_unstemmed | The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
title_short | The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
title_sort | effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467240/ https://www.ncbi.nlm.nih.gov/pubmed/34563187 http://dx.doi.org/10.1186/s12917-021-03014-5 |
work_keys_str_mv | AT kleinstephanie theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT nolteingo theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT rumstedtkatja theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT sehnmaximiliane theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT rauejonathanfriedemann theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT weinerfranziska theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT treesejuliasophie theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT beyerbachmartin theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT bachjanpeter theeffectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT kleinstephanie effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT nolteingo effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT rumstedtkatja effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT sehnmaximiliane effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT rauejonathanfriedemann effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT weinerfranziska effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT treesejuliasophie effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT beyerbachmartin effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy AT bachjanpeter effectoftreatmentwithpimobendanindogswithpreclinicalmitralvalvediseaseaplacebocontrolleddoubleblindedcrossoverstudy |